Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Long-term Activity Ratios (Summary)

Biogen Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Net fixed asset turnover 3.17 3.17 3.21 3.21 3.25 3.40 3.67 3.94 4.25 4.35 4.39 4.43 4.54 4.57 4.58 3.74 3.74 3.78 3.78 3.86
Net fixed asset turnover (including operating lease, right-of-use asset) 2.81 2.89 2.90 2.90 2.92 3.04 3.27 3.50 3.76 3.85 3.89 3.91 4.00 4.01 3.99 3.74 3.74 3.78 3.78 3.86
Total asset turnover 0.42 0.42 0.46 0.46 0.47 0.48 0.53 0.55 0.57 0.57 0.55 0.53 0.52 0.54 0.52 0.53 0.52 0.54 0.48 0.52
Equity turnover 0.81 0.90 0.96 1.01 1.06 1.09 1.18 1.26 1.33 1.28 1.15 1.08 1.02 1.09 1.00 1.03 0.96 1.05 0.90 0.97

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Biogen Inc. net fixed asset turnover ratio deteriorated from Q1 2022 to Q2 2022 but then slightly improved from Q2 2022 to Q3 2022.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Biogen Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Biogen Inc. total asset turnover ratio deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Biogen Inc. equity turnover ratio deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Net Fixed Asset Turnover

Biogen Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 2,508,500 2,589,100 2,531,800 2,733,800 2,778,900 2,775,000 2,694,000 2,852,600 3,376,100 3,681,600 3,534,300 3,671,300 3,600,100 3,616,700 3,489,800 3,526,300 3,439,000 3,356,500 3,131,100 3,307,000 3,077,800 3,078,400 2,810,700
Property, plant and equipment, net 3,266,400 3,355,100 3,372,800 3,416,400 3,410,700 3,442,200 3,438,300 3,411,500 3,359,900 3,330,700 3,281,600 3,247,300 3,138,100 3,077,500 3,013,800 3,601,200 3,538,900 3,409,000 3,334,700 3,182,400 2,995,900 2,827,600 2,610,900
Long-term Activity Ratio
Net fixed asset turnover1 3.17 3.17 3.21 3.21 3.25 3.40 3.67 3.94 4.25 4.35 4.39 4.43 4.54 4.57 4.58 3.74 3.74 3.78 3.78 3.86
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 11.82 11.57 11.18 11.00 10.75 10.41 9.67 8.73 8.15 7.38 11.50 11.23
Amgen Inc. 4.73 4.77 4.75 4.69 4.89 4.92 4.93 4.96 4.94 4.78 4.68 4.51
Bristol-Myers Squibb Co. 7.74 7.90 7.77 7.67 7.75 7.66 7.43 7.22 6.86 6.03 5.07 4.18
Eli Lilly & Co. 3.14 3.18 3.22 3.15 3.11 3.02 2.95 2.83 2.80 2.88 2.92 2.83
Gilead Sciences Inc. 5.01 5.13 5.18 5.27 5.40 5.27 5.06 4.90 4.74 4.70 4.90 4.91
Johnson & Johnson 5.29 5.21 5.07 4.95 4.95 4.79 4.59 4.40 4.53 4.57 4.75 4.65
Merck & Co. Inc. 2.89 2.85 2.73 2.53 2.57 2.61 2.55 2.67 2.80 2.99 3.15 3.11
Pfizer Inc. 6.47 6.64 6.12 5.46 4.79 3.89 3.31 3.01 2.98 3.21 3.47 3.71
Regeneron Pharmaceuticals Inc. 3.70 3.91 4.64 4.62 3.99 3.69 2.82 2.64 2.63 2.64 2.71 2.72
Thermo Fisher Scientific Inc. 5.12 5.02 4.87 4.71 5.54 5.83 5.85 5.45 5.50 5.37 5.42 5.38
Vertex Pharmaceuticals Inc. 7.78 7.59 7.18 6.92 6.84 6.54 6.51 6.47 6.51 7.42 6.55 5.59

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Net fixed asset turnover = (RevenueQ3 2022 + RevenueQ2 2022 + RevenueQ1 2022 + RevenueQ4 2021) ÷ Property, plant and equipment, net
= (2,508,500 + 2,589,100 + 2,531,800 + 2,733,800) ÷ 3,266,400 = 3.17

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Biogen Inc. net fixed asset turnover ratio deteriorated from Q1 2022 to Q2 2022 but then slightly improved from Q2 2022 to Q3 2022.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Biogen Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 2,508,500 2,589,100 2,531,800 2,733,800 2,778,900 2,775,000 2,694,000 2,852,600 3,376,100 3,681,600 3,534,300 3,671,300 3,600,100 3,616,700 3,489,800 3,526,300 3,439,000 3,356,500 3,131,100 3,307,000 3,077,800 3,078,400 2,810,700
 
Property, plant and equipment, net 3,266,400 3,355,100 3,372,800 3,416,400 3,410,700 3,442,200 3,438,300 3,411,500 3,359,900 3,330,700 3,281,600 3,247,300 3,138,100 3,077,500 3,013,800 3,601,200 3,538,900 3,409,000 3,334,700 3,182,400 2,995,900 2,827,600 2,610,900
Operating lease assets 424,500 321,100 359,000 375,400 389,100 402,500 414,500 433,300 434,200 436,200 422,000 427,000 422,000 434,400 447,800
Property, plant and equipment, net (including operating lease, right-of-use asset) 3,690,900 3,676,200 3,731,800 3,791,800 3,799,800 3,844,700 3,852,800 3,844,800 3,794,100 3,766,900 3,703,600 3,674,300 3,560,100 3,511,900 3,461,600 3,601,200 3,538,900 3,409,000 3,334,700 3,182,400 2,995,900 2,827,600 2,610,900
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 2.81 2.89 2.90 2.90 2.92 3.04 3.27 3.50 3.76 3.85 3.89 3.91 4.00 4.01 3.99 3.74 3.74 3.78 3.78 3.86
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
Vertex Pharmaceuticals Inc. 5.95 5.89 5.53 5.32 5.26 4.99 4.90 4.83 6.51 7.42 6.55 5.59

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = (RevenueQ3 2022 + RevenueQ2 2022 + RevenueQ1 2022 + RevenueQ4 2021) ÷ Property, plant and equipment, net (including operating lease, right-of-use asset)
= (2,508,500 + 2,589,100 + 2,531,800 + 2,733,800) ÷ 3,690,900 = 2.81

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Biogen Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Total Asset Turnover

Biogen Inc., total asset turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 2,508,500 2,589,100 2,531,800 2,733,800 2,778,900 2,775,000 2,694,000 2,852,600 3,376,100 3,681,600 3,534,300 3,671,300 3,600,100 3,616,700 3,489,800 3,526,300 3,439,000 3,356,500 3,131,100 3,307,000 3,077,800 3,078,400 2,810,700
Total assets 24,854,200 25,081,400 23,614,400 23,877,300 23,806,700 24,470,400 23,854,700 24,618,900 24,934,100 25,511,800 26,119,200 27,234,300 27,484,000 26,287,600 26,445,500 25,288,900 25,492,200 23,952,900 26,090,100 23,652,600 23,073,200 21,759,000 21,195,900
Long-term Activity Ratio
Total asset turnover1 0.42 0.42 0.46 0.46 0.47 0.48 0.53 0.55 0.57 0.57 0.55 0.53 0.52 0.54 0.52 0.53 0.52 0.54 0.48 0.52
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.41 0.40 0.40 0.38 0.37 0.36 0.33 0.30 0.27 0.24 0.37 0.37
Amgen Inc. 0.38 0.41 0.41 0.40 0.37 0.40 0.38 0.39 0.37 0.36 0.37 0.37
Bristol-Myers Squibb Co. 0.48 0.47 0.46 0.42 0.41 0.40 0.38 0.36 0.31 0.27 0.24 0.20
Eli Lilly & Co. 0.62 0.62 0.62 0.58 0.58 0.56 0.54 0.53 0.53 0.55 0.56 0.57
Gilead Sciences Inc. 0.43 0.43 0.43 0.40 0.41 0.39 0.37 0.36 0.37 0.39 0.37 0.36
Johnson & Johnson 0.55 0.54 0.53 0.52 0.51 0.51 0.49 0.47 0.47 0.51 0.53 0.52
Merck & Co. Inc. 0.55 0.53 0.51 0.46 0.51 0.52 0.51 0.52 0.53 0.52 0.57 0.55
Pfizer Inc. 0.51 0.52 0.50 0.45 0.39 0.33 0.29 0.27 0.24 0.25 0.29 0.31
Regeneron Pharmaceuticals Inc. 0.50 0.52 0.63 0.63 0.57 0.58 0.52 0.50 0.51 0.55 0.51 0.53
Thermo Fisher Scientific Inc. 0.49 0.47 0.44 0.41 0.53 0.57 0.54 0.47 0.44 0.43 0.44 0.44
Vertex Pharmaceuticals Inc. 0.52 0.54 0.56 0.56 0.57 0.55 0.53 0.53 0.53 0.53 0.54 0.50

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Total asset turnover = (RevenueQ3 2022 + RevenueQ2 2022 + RevenueQ1 2022 + RevenueQ4 2021) ÷ Total assets
= (2,508,500 + 2,589,100 + 2,531,800 + 2,733,800) ÷ 24,854,200 = 0.42

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Biogen Inc. total asset turnover ratio deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Equity Turnover

Biogen Inc., equity turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 2,508,500 2,589,100 2,531,800 2,733,800 2,778,900 2,775,000 2,694,000 2,852,600 3,376,100 3,681,600 3,534,300 3,671,300 3,600,100 3,616,700 3,489,800 3,526,300 3,439,000 3,356,500 3,131,100 3,307,000 3,077,800 3,078,400 2,810,700
Total Biogen Inc. shareholders’ equity 12,775,500 11,872,500 11,242,300 10,896,200 10,429,900 10,751,900 10,682,200 10,700,300 10,758,500 11,308,700 12,546,900 13,343,200 13,995,900 12,952,900 13,829,900 13,039,600 13,766,600 12,260,900 14,053,700 12,612,800 12,860,500 11,585,200 11,479,000
Long-term Activity Ratio
Equity turnover1 0.81 0.90 0.96 1.01 1.06 1.09 1.18 1.26 1.33 1.28 1.15 1.08 1.02 1.09 1.00 1.03 0.96 1.05 0.90 0.97
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 3.62 3.91 3.48 3.65 4.07 4.27 3.66 3.50 2.66 2.46
Amgen Inc. 6.71 10.17 26.68 3.63 2.96 2.93 2.56 2.58 2.17 2.17 2.41 2.30
Bristol-Myers Squibb Co. 1.43 1.45 1.49 1.29 1.22 1.21 1.14 1.12 0.79 0.71 0.62 0.51
Eli Lilly & Co. 2.90 3.40 3.14 3.15 3.58 4.15 3.69 4.35 4.81 5.61 7.50 8.56
Gilead Sciences Inc. 1.27 1.34 1.37 1.28 1.27 1.34 1.33 1.34 1.31 1.21 1.01 0.98
Johnson & Johnson 1.29 1.25 1.27 1.27 1.30 1.28 1.28 1.31 1.25 1.28 1.35 1.38
Merck & Co. Inc. 1.33 1.32 1.32 1.28 1.33 1.41 1.73 1.90 1.62 1.71 1.83 1.81
Pfizer Inc. 1.08 1.16 1.12 1.05 0.91 0.79 0.68 0.66 0.66 0.70 0.75 0.82
Regeneron Pharmaceuticals Inc. 0.64 0.69 0.83 0.86 0.78 0.82 0.77 0.77 0.81 0.88 0.66 0.71
Thermo Fisher Scientific Inc. 1.01 1.01 1.00 0.96 1.01 1.04 1.02 0.93 0.90 0.88 0.90 0.86
Vertex Pharmaceuticals Inc. 0.67 0.70 0.73 0.75 0.75 0.73 0.71 0.71 0.74 0.72 0.75 0.68

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Equity turnover = (RevenueQ3 2022 + RevenueQ2 2022 + RevenueQ1 2022 + RevenueQ4 2021) ÷ Total Biogen Inc. shareholders’ equity
= (2,508,500 + 2,589,100 + 2,531,800 + 2,733,800) ÷ 12,775,500 = 0.81

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Biogen Inc. equity turnover ratio deteriorated from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.